Navigation Links
Michael J. Fox Foundation Offers High-Quality LRRK2 Antibodies for PD Therapeutic Development
Date:3/23/2010

-- Part of larger effort to develop and distribute high-quality experimental tools that will speed progress toward better treatments for PD --

NEW YORK, March 23 /PRNewswire-USNewswire/ -- The Michael J. Fox Foundation announced that monoclonal LRRK2 antibodies, for use in understanding LRRK2 function and developing LRRK2-based therapeutics, will be available to Parkinson's researchers in academic/nonprofit and industry labs. In mid-April, the antibodies will be available free of charge to the entire PD research community for experimental use. This will allow researchers to undertake large-scale testing of the antibodies and provide feedback on their performance directly to MJFF. Once the best-performing antibodies have been identified, the Foundation will determine a practical distribution mechanism to make them available to the research community going forward.

"Our mission is to accelerate next-generation Parkinson's therapies on their path toward the clinic, and it is impossible to overstate access to high-quality, reliable experimental tools as a critical element of this push," said Katie Hood, CEO. "One of our top priorities is to mobilize financial and intellectual leadership around the creation of research tools and get them into scientists' hands to keep promising therapeutic strategies moving forward full-speed ahead."

The Foundation's ongoing investment in critical research tools is made possible through the generous support of The Brin Wojcicki Foundation.

About LRRK2 and LRRK2 Antibodies

LRRK2 is a Parkinson's-implicated gene discovered in 2004 that is now believed to be the single greatest genetic contributor to the disease. While it is the focus of intensive research in the Parkinson's field, a major roadblock to the successful development of LRRK2-based therapies is the lack of high-quality LRRK2 antibodies. Antibodies are used by researchers to identify where proteins can be found in the body, how they behave in cells, and how to manipulate their activity. Despite numerous attempts by individual researchers, high-quality LRRK2 antibodies are rare and often difficult for labs to obtain.

In 2009 MJFF convened a LRRK2 Antibodies Working Group composed of academic and industry researchers with specific expertise in LRRK2. At the recommendation of this group, MJFF engaged a company specializing in antibody development, Epitomics, Inc., to generate several highly sensitive and specific LRRK2 antibodies in large amounts.

The LRRK2 antibodies project is part of MJFF's broadly integrated strategy to drive LRRK2 research at every stage of drug development and accelerate the path of LRRK2-based drugs to the clinic.

How to Obtain Antibodies

For detailed scientific information on the LRRK2 antibodies and information on how to obtain them, researchers should visit PD Online Research (pdonlineresearch.org) or the new Research Tools page located on the Foundation's Web site (michaeljfox.org/research).

Next Focus Area under MJFF's Research Tools Effort: Pre-clinical Models

In addition to the antibodies announced today, the Foundation is working to develop and create distribution channels for new pre-clinical models of Parkinson's that better mimic the human condition. Multiple strains of new models are expected to come online for distribution over the course of 2010. There is an urgent need for such models, particularly for the development of treatments that could slow or stop the progression of PD (something no current treatment has been conclusively proven to do). The Michael J. Fox Foundation has been a field leader in the development of PD models for several years, with investments totaling approximately $13 million to date.

About The Michael J. Fox Foundation

The Michael J. Fox Foundation is dedicated to ensuring the development of better treatments, and ultimately a cure, for Parkinson's disease through an aggressively funded research agenda. MJFF has funded over $175 million in research to date. 

SOURCE Michael J. Fox Foundation

Back to top

RELATED LINKS
http://michaeljfox.org/research.cfm
http://www.pdonlineresearch.org/

'/>"/>

SOURCE Michael J. Fox Foundation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Delcath Systems Names Michael D. Dellario as Vice President, Global Marketing
2. Michael Langley, DVM, MBA, RAC Joins the Anson Group as a Regulatory Consultant
3. Oxford BioTherapeutics Appoints Michael Moore as Chairman
4. The Michael J. Fox Foundation Announces $1.5 Million in Funding to Advance Development of Drug Targets for Disease-Modifying Parkinsons Disease Treatments
5. Double Helix Consulting Enhances its Strategic Product Commercialization Services with Appointment of Michael Rizzo as Vice President
6. Dr. Michael Merzenich Joins Venerable Short List Honored for Cutting-Edge Neuroscientific Research
7. Clinical Therapeutics Announces the Addition of Michael G. Spigarelli, MD, PhD, as Editor for a Refocused Pediatric, Adolescent, & Maternal Therapeutics Section
8. BioStorage Technologies, Inc., Welcomes Catherine Michael as Global Head of Sample Management Operations
9. Ceregene Receives Additional Grant From Michael J. Fox Foundation to Expand Long-Term Testing of CERE-120 Patients
10. Covance Appoints Dr. Steven M. Michael as Vice President and Chief Scientific Officer of Global Bioanalytical Services
11. Statement From Michael Hansen, CEO of Elseviers Health Sciences Division, Regarding Australia Based Sponsored Journal Practices Between 2000 and 2005
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... Germany and GERMANTOWN, Maryland ... QGEN ; Frankfurt Prime Standard: QIA) today announced the ... Panels for gene expression profiling, expanding QIAGEN,s portfolio of ... panels enable researchers to select from over 20,000 human ... discover interactions between genes, cellular phenotypes and disease processes. ...
(Date:2/11/2016)...  Dovetail Genomics™ LLC today announced that it has ... planned metagenomic genome assembly service. Richard Green , ... method in a talk on Friday, February 12 at ... in Orlando, Fla. ... difficult. Using its proprietary Chicago ™ ...
(Date:2/11/2016)... ... February 11, 2016 , ... Global Stem Cells Group, ... Quito, Ecuador. The new facility will provide advanced protocols and state-of-the-art techniques in ... world. , The new GSCG clinic is headed by four prominent Ecuadorian ...
(Date:2/10/2016)... , Feb.10, 2016 ASAE is introducing ... Association Management Companies (AMC) the option of joining or ... annual fee determined by staff size, every employee in ... join ASAE and reap all available member benefits.   ... "Our new organizational membership options will allow organizations of ...
Breaking Biology Technology:
(Date:2/1/2016)... Rising sales of consumer electronics ... intuitive gesture control market size ... consumer electronics coupled with new technological advancements to drive ... through 2020   --> ... advancements to drive global touchfree intuitive gesture control market ...
(Date:1/27/2016)... CHESTER, Ohio , Jan. 27, 2016  Rite ... supplier based in West Chester, Ohio ... their award winning service staff, based in ... technical capacity and ability to provide modifications, installations and ... John Dovalina , CEO of PLUS, commented, "PLUS has ...
(Date:1/22/2016)... , Jan. 22, 2016 ... addition of the "Global Biometrics Market ... their offering. --> http://www.researchandmarkets.com/research/p74whf/global_biometrics ... "Global Biometrics Market in Retail Sector ... --> Research and Markets ( ...
Breaking Biology News(10 mins):